Company Overview of Kosan Biosciences Incorporated
Kosan Biosciences Incorporated develops anticancer agents through clinical procedures. Its KOS-953, Velcade, and Herceptin are used in the treatment of multiple myeloma and HER2-positive metastatic breast cancer. The company’s product portfolio also includes KOS-1584, an epothilone anticancer product candidate for solid tumors; and KOS-2187, a potent motilin receptor agonist for the treatment of GERD. In addition, its preclinical stage products also include KOS-1803 and KOS-2464. The company was incorporated in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Company.
3832 Bay Center Place
Hayward, CA 94545
Founded in 1995
Key Executives for Kosan Biosciences Incorporated
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Kosan Biosciences Incorporated, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.